Intelisci, renowned for securing top leaders and subject matter experts to drive innovation in drug and platform development, is committed to supporting emerging biotech companies with simple, transparent, and flexible recruitment solutions and vital advisory services to investors and founders. We are pleased to announce the addition of two esteemed members to our Scientific Advisory Board:
CEO and Venture Partner, Kent Rogers and Professor of Genetic Research, Dr. Dolan Sondhi.
Kent Rogers is the CEO of EveryONE Medicines, a Venture Partner at ARCH, and serves on the board of SlateRx. With over 30 years of experience in product commercialization, supply chain logistics, pricing, market access, and growth strategies, Kent is a seasoned executive. Previously, he was the Chief Commercial Officer of EQRx, where he led pre-commercialization strategies. During his tenure at OptumRx, he managed $40 billion in annual rebate agreements and over $16 billion in specialty medication procurement for Optum Specialty Pharmacy. Kent has also held leadership roles at Acorda Therapeutics, Schering-Plough, and Merck, and has served in multiple advisory roles for pharmaceutical firms, payer organizations, and the National Business Group on Health. He holds a B.S. from Indiana University and an M.B.A. from Emory University.
Dr. Dolan Sondhi is a highly accomplished research scientist with 25 years of experience in all aspects of clinical translation of AAV gene therapies for genetic disorders, with a particular focus on CNS and metabolic diseases. She is a Professor of Research in Genetic Medicine and the Associate Director of the Gene Therapy Core Facility at Weill Cornell Medicine. In addition to her academic roles, Dr. Sondhi serves on various corporate and scientific advisory boards. She earned her Ph.D. from Brown University.
Dolan has led several research programs in gene transfer of adeno-associated virus (AAV) to the CNS of animals, demonstrating the overall feasibility of the approach. She has also managed the translation of several of these programs from basic research to early phase clinical trials.
Matt Tong, CEO of Intelisci, expressed his enthusiasm for the new appointments: "We are thrilled to welcome Kent Rogers and Dr. Dolan Sondhi to our Scientific Advisory Board. It is incredible to have a Venture Partner from ARCH and a Professor of Research in Genetic Medicine join our team. Kent's extensive experience in product commercialization and strategic market access will provide invaluable insights to our emerging biotech clients, helping them navigate the complexities of bringing new therapies to market. Dr. Sondhi's groundbreaking work in AAV gene therapies and her deep expertise in translating research into clinical applications will be instrumental in advancing innovative treatments for genetic disorders. Their combined expertise will significantly enhance our ability to support the growth and success of our clients in the biotech industry."
Intelisci remains dedicated to providing emerging biotech companies with unparalleled recruitment solutions and advisory services, driving innovation and success in the field of drug and platform development.
Kommentare